describe a strong association between HIV and stroke in a prospective, case-control, hospital-based study in Malawi, a low-income country in sub-Saharan Africa with a high prevalence of HIV infection. The investigators aimed to determine the risk of stroke independently attributable to HIV, antiretroviral therapy (ART), and hypertension. HIV infection was the predominant risk factor for stroke in individuals aged #45 years, whereas hypertension surpassed HIV infection (adjusted odds ratio 8.57 vs 2.10) in older adults. Furthermore, lower relative CD4 1 lymphocyte count in untreated HIV and HIV infection with recent initiation of ART also were associated with increased risk of stroke.
This study provides critical information in the evaluation of HIV infection and stroke in Africa, particularly given the likely obstacles to conducting longitudinal analyses in developing nations. It supports prior reports that HIV infection is an independent risk factor for stroke, and demonstrates that ART-early in its use-further contributes to this risk. By evaluating hypertension as another important risk factor, the authors parse out the relative importance of these 2 major risk factors in this population, with the novel finding that hypertension is a more important risk factor than HIV in older Malawian adults. The increased risk of stroke in younger HIV-infected patients found by this study is consistent with prior reports. 4 The study has limitations, especially with regard to generalizability. The investigation was conducted in an extremely poor country with a paucity of resources including limited access to highly active or combination ART. The finding by the authors of increased risk of stroke early in the course of ART is only valid for nucleoside and non-nucleoside reverse transcriptase inhibitors since none of the patients in this study were on protease inhibitors, a class of drugs strongly associated with hyperlipidemia and insulin resistance. 7 Furthermore, those starting ART in the first 6 months had very low CD4
1 counts, suggesting that many were in advanced stages of AIDS. Because of the observational nature of these data, subjects with recent initiation of ART may have differed in other substantive ways from the group with longer-term treatment (including compliance). Therefore, the adverse impact of ART on the risk of stroke should be considered in the context of duration, severity, and the stage of HIV infection. The large confidence intervals associated with the risk of stroke in patients on ART for less than 6 months suggest limited power to allow unequivocal conclusions. Similar to concerns about generalizability of the patient population, controls were selected from the community, not from a group of hospitalized individuals. Stroke patients in this study may therefore have had other medical comorbidities or infections that could not be evaluated by the investigators. These concomitant conditions might not be found in the community controls, yet could explain the apparent associations. Moreover, information about specific HIV-associated opportunistic or coinfections was not available in this cohort.
The study's finding that decreasing CD4 1 lymphocyte count is associated with an increasing risk of stroke may further support a role of underlying HIV infection in the stroke cases. Interestingly, the authors did not find a similar association for increasing viral load. It remains unclear which marker better estimates this risk, given that others have described the opposite pattern; that is, viral load, not CD4 1 count, associated with an increased risk of stroke. 4 Although the extent of immunodeficiency represented by CD4 1 lymphocyte count certainly influences the risk of stroke, a direct viro-toxic effect of HIV on the arteries and its role in accelerated atherosclerosis cannot be undermined. 8, 9 The theory that vascular risk might directly relate to viral titers has not been studied systematically. Still, in developing countries with inherently limited resources, routine performance of both tests may not prove a cost-effective strategy. 10 Determination of the predictive value of each test in terms of stroke and cardiovascular risk needs further investigation.
We commend Benjamin et al. in meticulously conducting a prospective study of a reasonable size to answer a complex question. Their investigation included a cohort of HIV-infected individuals not on ART, an elusive yet ideal population for delineating the risk of stroke directly related to HIV infection. It also further supports the importance of prevention and treatment of standard vascular risk factors (in this case, hypertension), particularly in older adults, even in low-income countries with high rates of HIV disease.
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